Blueprint Medicines Corporation (NASDAQ:BPMC) Files An 8-K Regulation FD Disclosure

ME Staff 8-k
-
0

Blueprint Medicines Corporation (NASDAQ:BPMC) Files An 8-K Regulation FD Disclosure
Item 7.01Regulation FD Disclosure.

On September 10, 2017, Blueprint Medicines Corporation (the “Company”) issued a press release announcing new data from its ongoing Phase 1 clinical trial evaluating BLU-554 for the treatment of advanced hepatocellular carcinoma. The data were presented on Sunday, September 10, 2017 in an oral presentation at the European Society for Medical Oncology (“ESMO”) 2017 Congress in Madrid, Spain. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K, and a copy of the presentation at the ESMO 2017 Congress is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

In addition, on September 11, 2017, the Company hosted an investor conference call and live webcast to discuss the data presented at the ESMO 2017 Congress. A copy of the presentation from the conference call is furnished as Exhibit 99.3 to this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1, 99.2 and 99.3, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1

Press release issued by Blueprint Medicines Corporation on September 10, 2017

99.2

Presentation by Blueprint Medicines Corporation at the ESMO 2017 Congress on September 10, 2017

99.3

Presentation by Blueprint Medicines Corporation at investor conference call on September 11, 2017


Blueprint Medicines Corp Exhibit
EX-99.1 2 bpmc-20170910ex991574749.htm EX-99.1 bpmc_Ex99_1 Exhibit 99.1   Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma   – Encouraging Clinical Activity Observed in Heavily Pre-Treated Patients with FGFR4-Driven HCC – –  Data Support Patient Selection Strategy for First Potential Biomarker-Driven Treatment Approach in HCC – – Blueprint Medicines to Host Investor Conference Call and Webcast on Monday,…
To view the full exhibit click here

About Blueprint Medicines Corporation (NASDAQ:BPMC)

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. The Company focuses on crafting drug candidates with therapeutic windows that provide clinical responses to patients without adequate treatment options. The Company has developed a small molecule drug pipeline in cancer and a genetic disease. The Company’s drug candidate, BLU-285, targets KIT Exon 17 mutants and PDGFRa D842V, which are abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. It is engaged in developing BLU-285 for patients with systemic mastocytosis (SM), a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor (GIST). Its drug candidate, BLU-554, targets FGFR4, a kinase that is aberrantly activated and is a driver of disease in a defined subset of patients with hepatocellular carcinoma (HCC).